SV7 Impact Medicine Fund LP 3
3 · Xilio Therapeutics, Inc. · Filed Oct 21, 2021
Insider Transaction Report
Form 3
SV7 Impact Medicine Fund LP
10% Owner
Holdings
Series B Convertible Preferred Stock
Exercise: $0.00→ Common Stock (998,544 underlying)- (indirect: See footnote)
Series B Convertible Preferred Stock
Exercise: $0.00→ Common Stock (998,544 underlying) Series C Convertible Preferred Stock
Exercise: $0.00→ Common Stock (302,588 underlying)- (indirect: See footnote)
Series C Convertible Preferred Stock
Exercise: $0.00→ Common Stock (302,588 underlying)
Footnotes (2)
- [F1]Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (together, the "Preferred Stock") will automatically convert into 0.1053 shares of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"). The Preferred Stock has no expiration date.
- [F2]Consists of shares of common stock underlying shares of convertible preferred stock held by SV7 Impact Medicine Fund LP, via its general partner SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of our board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to these shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of the shares held herein except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom.